$GH

Hidalgo Medina Manuel sold $279K of GH

Hidalgo Medina Manuel sold 1,700 shares of Guardant Health, Inc. (GH) at an average of $164.24 ($163.94–$164.61, $0.28M total) across 2 trades on 2026-08-05.

Original reporting
SEC EDGAR · Hidalgo Medina Manuel
Published Aug 6, 2026, 9:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 10:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest information is the specific open-market sale size, price range, and post-transaction holdings, which can influence short-term sentiment but lacks fundamental context.

02

Market read

Traders may monitor insider selling as a sentiment input, but this disclosure alone does not provide a new operational or financial catalyst.

03

What to watch

The filing does not state the director’s rationale, tax considerations, or whether other planned sales occurred; without those, the signal-to-noise is low.

Relevance 4/10Novelty 5/10Timing: Form 4 filed 2026-08-06 after-hours, reflecting insider sale disclosed today

Background

The article is a SEC Form 4 insider transaction disclosure for Guardant Health, Inc., reported by a director.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health director Hidalgo Medina Manuel sold 1,700 shares in open-market trades for about $279.2K, per a new Form 4 filed today.

Expected impact

Near-term impact is likely limited, though it can add modest sell-side optics if the market is sensitive to insider behavior.

Evidence & confidence

The disclosure is primary-source (Form 4) and time-stamped, but the article provides no accompanying company-specific negative news, guidance change, or material event.

Market effects

Minimal, as the event is an individual insider transaction without sector-wide regulatory or clinical implications.

None indicated; this is a US-listed company insider sale disclosure.

None indicated.

Counterpoint

Because the sale is not tied to a stated 10b5-1 plan, some traders may over-interpret it as a signal, even though director sales are often liquidity-driven.

Key entities

  • Guardant Health, Inc.

    US-listed company (GH) whose director reported an open-market sale of shares via Form 4.

  • Hidalgo Medina Manuel

    Director who sold 1,700 shares across two trades at about $163.945 to $164.605 per share.

Related articles

$GHHighAI 9/10

Guardant Health (GH) Q2 2026 Earnings Call Transcript

Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.

$GHMedAI 8/10

New blood test to detect colon cancer clears FDA approval

The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.

$GHMedAI 8/10

Guardant Health, Inc. Q2 2026 Earnings Call Summary

Guardant Health reported 44% YoY Q2 2026 revenue growth, citing strong Oncology and Screening performance. It raised full-year 2026 revenue guidance to $1.34B-$1.36B and expects lower Shield cost per test. FDA approval of Guardant360 Liquid CDx and UnitedHealth coverage for Shield from Aug. 1, 2026 are key catalysts.

$GHHighAI 9/10

Why is Guardant Health stock surging today?

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade Investing.com -- Guardant Health stock surged 8.8% in after-hours trading after the Palo Alto-based liquid biopsy pioneer reported second-quarter 2026 results that significantly exceeded revenue expectations, with sales reaching $335 million — a 44% year-over-year increase that beat the Wall Street consensus of roughly $314 million by approximately 6.4%.

$GHMedAI 8/10

Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars

Diagnostics company Guardant Health (NASDAQ: GH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 44.3% year on year to $335 million. The company’s full-year revenue guidance of $1.35 billion at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP loss of $0.42 per share was 7.8% below analysts’ consensus estimates. Is now the time to buy Guardant Health? Find out by accessing our full research report, it’s free.